Cogent Biosciences, Inc. (COGT) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST).
Is Cogent Biosciences, Inc. stock overvalued or undervalued in 2026?
As of October 30, 2026, Cogent Biosciences, Inc. (COGT) trades at $31.02 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Cogent Biosciences, Inc.
Market cap $5B · 52 weeks $14 – $43 (28 % below the high) · P/E no earnings · Dividend none · Next earnings November 6, 2026 · expected EPS $-0.56 · Closing price, Oct 30 · accounts published Aug 10.
- Valuation: P/E — (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 4 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.0 %, fails.
- Market cap / Cash 5.5×, fails.
- Cash Runway 41 meses, passes.
- Total Debt 0.3×, passes.
- Annual cash burn $1.64, info.
Against its peers (reference peers) — Cogent Biosciences, Inc.: P/E —; EV/EBITDA —; ROIC -50.1 %; $5.4B. Nurix Therapeutics, Inc. (P/E 11.6×; EV/EBITDA 7.0×; ROIC 25.9 %; $2.9B), Incyte Corporation (P/E 64.0×; EV/EBITDA 24.2×; ROIC 6.0 %; $24.5B), PTC Therapeutics, Inc. (P/E —; EV/EBITDA 30.4×; ROIC 4.9 %; $5.0B).
Profitability
| Return on Equity | -72.57% |
| Return on Invested Capital | -50.09% |
| Return on Assets | -45.20% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.46 |
| Current Ratio | 13.57 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 9.52 |
Price Performance
| 1 month | +0.00% |
| 3 months | -20.17% |
| Year-to-date | -12.67% |
| 1 year | +90.31% |
| 3 years | +262.38% |
| 5 years | +245.05% |
Related companies: INCY · IDYA · TNGX · NRIX · RCUS
Explore sector: Healthcare · Biotechnology
More sections of COGT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks